MK-677 (Ibutamoren) Complete Research Guide: Mechanisms, Benefits & Safety

April 3, 2026
Peptide Guides

What Is MK-677?

MK-677, also known as ibutamoren or ibutamoren mesylate, is a non-peptide growth hormone secretagogue that acts as a potent, orally active ghrelin receptor agonist. Unlike traditional peptide-based growth hormone secretagogues (such as GHRP-2 or GHRP-6), MK-677 is a small molecule compound that is stable when taken orally — a property that has made it particularly valuable in research settings where parenteral administration is impractical.

MK-677 was originally developed by Merck & Co. and has been studied extensively in clinical trials for conditions including muscle wasting, growth hormone deficiency, and age-related decline in GH/IGF-1 levels. While it has not received FDA approval for therapeutic use, its well-characterized pharmacology makes it one of the most rigorously studied compounds in the growth hormone axis.

Mechanism of Action

MK-677 stimulates the release of growth hormone (GH) through two complementary mechanisms:

Free Tool

Peptide Reconstitution Calculator

Convert vial strength, water volume, and desired dose into precise syringe units. Works for BPC-157, TB-500, GHK-Cu, and all research peptides.

Try the Calculator →

Ghrelin receptor agonism: MK-677 binds the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. This stimulates pulsatile GH release from the anterior pituitary in a pattern that mimics physiological secretion.
GHRH amplification: MK-677 potentiates the effect of endogenous growth hormone-releasing hormone (GHRH), increasing both the amplitude and frequency of GH pulses without suppressing the body’s natural regulatory feedback.

The downstream effect is a sustained elevation of both growth hormone and insulin-like growth factor 1 (IGF-1). Because MK-677 works within the body’s natural pulsatile secretion framework, it avoids the continuous GH elevation and associated feedback suppression seen with exogenous recombinant GH administration.

Dosage in Preclinical and Clinical Research

MK-677 is notable for having an unusually robust clinical research record compared to most compounds in this category. Published dose parameters span animal studies through Phase II human trials.

Rodent Studies

In rat and mouse models, MK-677 has been administered orally at doses of 1–10 mg/kg/day. Significant GH and IGF-1 elevations are observed at the lower end of this range, with body composition changes (increased lean mass, reduced fat mass) documented at sustained dosing in aged animal models.

Human Clinical Studies

Published clinical trials have used MK-677 at 10–50 mg/day orally in adult subjects. Key findings across these trials include:

10 mg/day: Produces meaningful IGF-1 elevation with a favorable side effect profile; studied in frail elderly populations
25 mg/day: Most commonly studied dose; produced 60–100% increases in IGF-1 in multiple trials spanning 8 weeks to 2 years
50 mg/day: Maximal GH/IGF-1 response with increased incidence of side effects including water retention and appetite stimulation

A landmark 2-year trial (Nass et al., 2008) examined MK-677 at 25 mg/day in elderly subjects and found sustained IGF-1 elevation, improved muscle mass, and increased bone mineral density, with the main adverse effects being edema and insulin resistance at higher doses.

Research Applications

MK-677 has been investigated in the following research contexts:

Sarcopenia and muscle wasting: Multiple trials have examined MK-677’s ability to preserve or restore lean body mass in elderly and catabolic states. Significant improvements in muscle cross-sectional area and functional measures have been observed.
Bone mineral density: IGF-1 elevation from MK-677 stimulates bone remodeling. Studies in osteoporosis models show increased bone turnover markers and improvements in density metrics.
Sleep architecture: MK-677 increases slow-wave (deep) sleep duration and REM sleep in research subjects, consistent with the known role of GH in sleep regulation. This has made it a subject of interest in sleep quality research.
Metabolic research: MK-677’s effects on lipid metabolism, insulin sensitivity, and body composition make it relevant to metabolic syndrome research models.
GH deficiency models: In subjects with documented GH deficiency, MK-677 normalizes IGF-1 levels without the administration complexity of injectable recombinant GH.
Cognitive function: Emerging research has explored the relationship between GH/IGF-1 axis activity and cognitive performance in aging models, with MK-677 as a research tool.

Comparison with Peptide-Based Secretagogues

MK-677 occupies a unique position in growth hormone secretagogue research due to its oral bioavailability. Peptide-based GHS compounds such as GHRP-2, GHRP-6, and Ipamorelin share the same GHS-R1a mechanism but require parenteral administration and have shorter half-lives (minutes to hours versus MK-677’s approximate 24-hour half-life).

Key comparative characteristics:

Half-life: MK-677 ~24 hours vs. peptide GHS compounds 1–4 hours
Route: MK-677 oral vs. peptide GHS subcutaneous injection
Selectivity: MK-677 is highly selective for GHS-R1a; some peptide GHS compounds also bind CD36 or other receptors
Research literature: MK-677 has a larger clinical trial base; peptide GHS compounds have more preclinical mechanistic data

Storage and Handling

MK-677 is supplied as a powder or in capsule form. Storage considerations:

Powder: Store at −20°C for long-term stability (up to 2 years); refrigerator (2–8°C) stable for up to 12 months
Protect from moisture and light
Capsule formulations: Store at room temperature (15–25°C) in a sealed container away from humidity
Solutions: Not recommended for long-term storage; prepare fresh from powder for aqueous administration models

See our complete guide on how long peptides last at room temperature for broader storage considerations.

Quality and Purity Standards

As a non-peptide small molecule, MK-677 purity assessment uses similar analytical methods to peptide compounds. Research-grade MK-677 should be verified by:

HPLC analysis confirming ≥98% purity
Mass spectrometry confirming correct molecular weight (MW 624.77 g/mol for the mesylate salt)
Certificate of Analysis (CoA) from an independent third-party laboratory

At Prax Peptides, all compounds are supplied with third-party CoA documentation. Learn more about how to test peptides and research compounds for purity.

Frequently Asked Questions

Is MK-677 a peptide?

No. Despite being categorized and sold alongside research peptides, MK-677 is a small molecule compound, not a peptide. It mimics the action of the peptide hormone ghrelin at the GHS-R1a receptor but has a fundamentally different chemical structure — which is precisely what enables its oral bioavailability.

How does MK-677 differ from SARMs?

MK-677 is frequently grouped with SARMs (selective androgen receptor modulators) in research catalogs, but they have entirely different mechanisms. SARMs target androgen receptors to modulate muscle and bone tissue. MK-677 targets the ghrelin receptor to stimulate growth hormone secretion. They operate on completely distinct biological pathways.

What is the research basis for MK-677’s effects on sleep?

A 1997 study by Copinschi et al. demonstrated that MK-677 at 25 mg/day significantly increased slow-wave sleep duration and REM sleep. The mechanism is consistent with the established role of growth hormone in promoting deep sleep stages, as GH is predominantly released during slow-wave sleep in healthy individuals.